Clinical Trial Update: Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating lenalidomide in combination with gemcitabine for relapsed or refractory peripheral T-cell lymphomas has been terminated. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphomas

Drugs mentioned

• Gemzar (gemcitabine)
• Revlimid (lenalidomide)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Peripheral T-cell Lymphomas (PTCL) | Phase 1, Phase 2 | Status: TERMINATED